scholarly journals Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab

2012 ◽  
Vol 6 ◽  
pp. CMO.S5055 ◽  
Author(s):  
Miriam López-Gómez ◽  
María Merino ◽  
Enrique Casado
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibody ◽  
Metastatic Colorectal Cancer ◽  
Systemic Chemotherapy ◽  
Term Treatment ◽  
Long Term Treatment

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy. In recent years many anti-EGFR targets have been developed. Among them, panitumumab, a fully human IgG2 monoclonal antibody has shown important benefits in the treatment of this disease.

INFLUENCE OF THE AGE FACTOR AND TUMOR IMMUNOPHENOTYPE ON THE EFFECTIVENESS OF CYTOREDUCTIVE OPERATIONS IN METASTATIC COLORECTAL CANCER

2019 ◽  
Vol 65 (6) ◽  
pp. 855-862
Author(s):  
Nikolay Maystrenko ◽  
Georgiy Manikhas ◽  
Aleksey Sazonov ◽  
Vadim Chirskiy ◽  
Alina Yerokhina
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Significant Risk ◽  
Biological Properties ◽  
Term Treatment ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Long Term Treatment ◽  
Age Factor

Aim of the study. To analyze the effectiveness and safety of cytoreductive interventions in patients with IV stage colorectal cancer in account of the age factor and to assess the effect of the molecular biological properties of the tumor on long-term treatment results. Materials and methods. A comparative evaluation of the results of surgical treatment of metastatic colorectal cancer in patients of various age groups was carried out. The clinical significance of immunohistochemical markers for predicting long-term treatment outcomes has been studied. Results. The most significant risk factors for the development of postoperative complications were identified. The prognostic value of immunohistochemical markers such as the proliferative index of stem cancer cells (ALDH + Ki-67 +) and the chemokine receptor CXCR4 has been established. Conclusion. A comprehensive analysis of the molecular biological properties of the tumor, coupled with an assessment of the functional operability of patients, provides a personalized approach to the choice of surgical tactics in patients with stage IV colorectal cancer, which allows counting on the encouraging results of cytoreductive interventions.

539 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8

2021 ◽  
Vol 160 (6) ◽  
pp. S-111
Author(s):  
Kathryn A. Peterson ◽  
Mirna Chehade ◽  
Joseph A. Murray ◽  
Gary W. Falk ◽  
Nirmala Gonsalves ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Term Treatment ◽  
Eosinophilic Gastritis ◽  
Long Term Treatment

scholarly journals Oxaliplatin for Metastatic Colon Cancer in a Patient with Renal Failure

2008 ◽  
Vol 2 ◽  
pp. CMO.S412
Author(s):  
Kenji Katsumata ◽  
Tetsuo Sumi ◽  
Tatehiko Wada ◽  
Yasuharu Mori ◽  
Masayuki Hisada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Renal Failure ◽  
Term Treatment ◽  
Pharmacokinetic Data ◽  
Metastatic Colon Cancer ◽  
Standard Regimen ◽  
Long Term Treatment ◽  
Before And After ◽  
Cecal Cancer

Objective Oxaliplatin, a key part of the standard regimen for colorectal cancer in Western countries, has become available in Japan. In a hemodialysis patient with cecal cancer, we investigated the efficacy, safety, pharmacokinetics, and dialysability of oxaliplatin. Methods A 65-year-old man who had cecal cancer was treated with oxaliplatin (40 mg/m2) and l-leucovorin(l-LV) (200 mg/m2), which were administered simultaneously over 120 min via the side and main arms of a Y-tube, respectively. Then 5-FU (400 mg/m2) was administered rapidly via the side tube, followed by 5-FU (2,000 mg/m2) over 46 hours via the main tube. The patient had chronic renal failure due to diabetic nephropathy and hemodialysis was performed 3 times a week. Blood samples were collected from the dialyzer before and after each hemodialysis session to examine platinum clearance. Results The patient received 3 courses of oxaliplatin before he died of cancer. During hemodialysis, the platinum level fell from 0.32 μg/mL to 0.15 μg/mL. Conclusion Since patients with renal failure have various associated disorders and oxaliplatin has a long half-life, it is necessary to obtain more pharmacokinetic data to investigate its accumulation and dialysability during long-term treatment. Such data will assist in treating the rapidly increasing number of hemodialysis patients with colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document